265 related articles for article (PubMed ID: 8914038)
1. A randomized controlled study of iron supplementation in patients treated with erythropoietin.
Macdougall IC; Tucker B; Thompson J; Tomson CR; Baker LR; Raine AE
Kidney Int; 1996 Nov; 50(5):1694-9. PubMed ID: 8914038
[TBL] [Abstract][Full Text] [Related]
2. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
Park L; Uhthoff T; Tierney M; Nadler S
Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
[TBL] [Abstract][Full Text] [Related]
3. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
4. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
Saltissi D; Sauvage D; Westhuyzen J
Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
[TBL] [Abstract][Full Text] [Related]
5. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients.
Johnson DW; Herzig KA; Gissane R; Campbell SB; Hawley CM; Isbel NM
Nephrol Dial Transplant; 2001 Sep; 16(9):1879-84. PubMed ID: 11522873
[TBL] [Abstract][Full Text] [Related]
6. Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency.
Sultana T; DeVita MV; Michelis MF
Int Urol Nephrol; 2016 Sep; 48(9):1519-24. PubMed ID: 27170339
[TBL] [Abstract][Full Text] [Related]
7. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
8. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy.
Biesma DH; Van de Wiel A; Beguin Y; Kraaijenhagen RJ; Marx JJ
Eur J Clin Invest; 1994 Jun; 24(6):426-32. PubMed ID: 7957497
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
Wingard RL; Parker RA; Ismail N; Hakim RM
Am J Kidney Dis; 1995 Mar; 25(3):433-9. PubMed ID: 7872321
[TBL] [Abstract][Full Text] [Related]
12. Iron status markers and serum erythropoietin in 120 mothers and newborn infants. Effect of iron supplementation in normal pregnancy.
Milman N; Agger AO; Nielsen OJ
Acta Obstet Gynecol Scand; 1994 Mar; 73(3):200-4. PubMed ID: 8122498
[TBL] [Abstract][Full Text] [Related]
13. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
14. [Effect of human recombinant erythropoietin (r-EPO) on behavior of iron status parameters in patients with chronic renal failure treated with dialysis].
Debska-Slizień A; Biedunkiewicz B; Rutkowski B
Pol Arch Med Wewn; 1994 Sep; 92(3):207-15. PubMed ID: 7808929
[TBL] [Abstract][Full Text] [Related]
15. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
Fishbane S; Frei GL; Maesaka J
Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
[TBL] [Abstract][Full Text] [Related]
16. Effective utilization of erythropoietin with intravenous iron therapy.
Bhandari S; Brownjohn A; Turney J
J Clin Pharm Ther; 1998 Feb; 23(1):73-8. PubMed ID: 9756115
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
[TBL] [Abstract][Full Text] [Related]
18. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.
Charytan C; Goldfarb-Rumyantzev A; Wang YF; Schwenk MH; Spinowitz BS
Am J Nephrol; 1998; 18(6):498-503. PubMed ID: 9845824
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]